Avanir Pharmaceuticals, Inc. (AVNR) Posts Q3 EPS Loss of $0.13, Revenues Fall Inline
Tweet Send to a FriendGet Alerts AVNR Hot Sheet
Price: $3.40 +4.62%
EPS Growth %: +25.0%
Financial Fact:
Other, net: 197
Today's EPS Names:
TARO, SENEA, UQM, More
EPS Growth %: +25.0%
Financial Fact:
Other, net: 197
Today's EPS Names:
TARO, SENEA, UQM, More
Trade AVNR Now!
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) reported Q3 EPS of ($0.13), $0.01 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $2.53 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- salesforce.com, Inc. (CRM) Reports In-Line Q1 EPS; Issues In-Line Q2, FY14 Outlook
- Mentor Graphics Corp (MENT) Tops Q1 EPS by 5c; Guides Q2, FY14
- Shoe Carnival, Inc. (SCVL) Tops Q1 EPS by 6c, Guides Q2 In-Line
Create E-mail Alert Related Categories
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
